Introduction The Indian Pharmaceutical Industry is in the front rank of India’s science based industries. It is a highly organized sector. The Industry is estimated to be of worth $ 4.5 billion, with growth of about 8 to 9% annually. It ranks very high in terms of technology, quality and range of manufactured medicines. From simple headache pills to heavy antibiotics and complex cardiac compounds, almost each and every type of medicine is now made indigenously. It meets around 70% of the country's demand for bulk drugs, drug intermediates, tablets, chemicals, capsules, pharmaceutical formulations orals and injectable. There are 250 large units and 8000 Small Scale Units, which forms the core of the Indian pharmaceutical industry (including 5 Central Public Sector Units). Indian Pharmaceutical industry in 2012 – 2014 Increasing sales of generic medicines, growth in chronic therapies and greater penetration in rural markets are reasons behind a double-digit growth i.e. 13-14% in 2013. The year 2012 closed with growth of 12%. It attracted FDI worth 9,776 million USD between April 2000 to November 2012. India's exports of drugs and pharmaceuticals grew by 27% to Rs 60,000 crore (11.19 billion USD) for the year ended March 2012. This industry is projected to show double-digit growth in future owing a rise in pharmaceutical outsourcing and rising investments by multinational companies. Most of the companies in this sector have shown considerable decline in growth in the first half of 2011. Companies like Cipla, Torrent and IPCA which focused on Indian market are already in trouble. Growth rates of companies such as Dr. Reddy and Ranbaxy have come down. On the other hand Sun and Lupin are showing growth because to the shift of fo... ... middle of paper ... .... The return on net worth in 2010 was 18.31% to 16.99% in 2013. The dividend payout ratio is maximum in 2011 of 27.23 % . The debt equity ratio has remained very low that is .11 which is far below than the ideal ratio of 2:1. EPS has increased from Rs. 9.99 in 2009 to about Rs 18.77 in 2013 with gradual increase throughout. The DPS for two years has remained constant in 2009 to 2013 of Rs. 2. Book value per share EPS has almost remained same throughout i.e. from around Rs. 5.99 in 2009 it has become Rs. 5.88 in year 2013. (http://www.moneycontrol.com/news/business/indias-pharma-industry-seeing-rapid-growth-wockhardt_1013349.html) CONCLUSION: From the above table and interpretation it can be concluded that CIPLA is under performing decently as the dividend payment is constant and increasing EPS. Thus, Investing in this company is therefore could be a good option.
...s are doing well and over the many years have gone up. The company has not lawsuits currently pending which is good. The company as a whole seems to be growing even when the market is down.
The stock price is currently 103.31, down from a recent high of 121.50. The P/E ratio is declining at 28 and beta at .67, which is expected to grow closer to 1.0. A recent earnings surprise last December yielded a 15% difference from the lower expectations and the latest earnings reports late last month also surprised investors. Estimates for the 2000 fiscal year are being raised by a large majority of analyst who believe that earnings per share will increase and the stock price will reach close to 150.
Another observation is that GM looks to use more debt financing that equity financing for funding their activities. The debt to equity ratio has steadily decreased over the past five years and is higher that the industry average. Also, the current and quick ratios are much lower than the industry averages. This again can pose so...
Looking at the individual ratios seen in exhibit 1 and comparing it to the industry average shown in exhibit 2 gives a sense of where this company stands. Current ratio and quick ratio are really low and have been decreasing. For 1995, the current ratio is 1.15:1, which is less than the industry average of 1.60:1, however to give a better sense of where this stands in the industry, as seen in exhibit 3, it is actually less than the average of the bottom 25% of the industry. The quick ratio is 0.61 is less than the industry is 0.90. Both these ratios serve to point out the lack of cash in this company. The cash flow has been decreasing because, it takes longer to get the money from customers, but the company still needs to pay for its purchases. Also, the company couldn’t go over the $400,000 loan limit, so they were forced to stretch their cash.
The pharmaceutical industry is relatively immune from the effects of economic cycles. Demand for the industry's product remains constant in up and down economic cycles as market demand is a function of the overall health of the population. However the globalization of the pharmaceutical industry increases the risk associated with foreign investments and exchange rates. The firms in this industry seek to minimize risks by using hedging practices such as foreign currency forward-exchange contracts, borrowing in foreign markets, and using currency swaps.
Apple’s debt to equity ratio is not very high compared to the industry average of 2.23. The Debt to Equity Ratio of 2014 is 1.08, in which the normal ratio should be less than 1. This ratio of 1.08 shows that the company is financing more assets with debt than equity. In spite
This is a good sign, showing that the company is able to pay its current liabilities using its current assets. The debt-to-equity ratio of Kodak is the first signal within the ratio that the company is not performing well. Generally, this ratio should be below 1 and for Kodak in 2014 it was 8.83. Their equity is almost non-existent and this is signaling very weak balance sheet strength.
...rs, setting a good trend for the corporation. They also have a very low debt-to-equity ratio, indicating that they have enough equity to easily pay off any funds acquired from creditors. As a creditor I would feel safe in lending them funds for any future projects or endeavors.
The current cash debt coverage ratio dropped from 3.38 to 2.69. This is because the increase in cash from operating activities (26%) is lower than the increase in the average total current liabilities (58%). Again, IQ seems to remain highly liquid nevertheless.
Debt-to-equity ratio: The debt-to-equity ratio for 2010 is $3,738,150/ $4,781,471=.782. For the year 2011, the debt-to-equity ratio is $2,722,811/ $5,672,551=.478. This number is calculated by Total Liabilities / Owners’ Equity
For commodity generic drugs, Teva has an opportunity to expand its core business into emerging markets, but there it will have to face institutional voids because such markets are driven by physicians and both physician and other people are not aware about the effectiveness of generic drugs. To cope with the challenge of institutional voids Teva have to look for some competent small pharmaceutical firms for acquisition and some big firms for the joint venture. For changing the perceptions of people and physicians, Teva will require to run marketing campaigns and direct approaches to physicians to develop a market for their products.
In 1993 the Debt to Equity Ratio was .45. In 1994 it was .68 and in 1995 it was .73. This is a trend that Clarkson will have to take into consideration as he refinances his company.
The basic earnings per ordinary share in 2016 is RM19.14 and RM14.30 in 2015. This shows that the ordinary share had been increased RM4.84 compare to 2016 based on 2015. In the other hand, this company had declared a first interim single-tier dividend of 10 sen per ordinary share amounting to RM22.88 million in respect of the financial year ended 31 December 2016. They sold their ordinary shares of RM400,000,000 units of RM0.50 per each in 2016 and RM200,000,000 units of RM0.50 per each in 2015 to their shareholders. It is increased from 2015 to 2016 with 200,000,000 units. The other investments that available for sale is RM1000 same as in 2015 and 2016.
Whereas, China’s annual herbal drug production is about US $48 billion with export of US $3.6 billion. Currently, United States has the largest share for Indian botanical products which accounts for about 50% of its total export. The major importers of herbal medicine from China are Japan, Hong Kong, Korea and Singapore which accounts for 66%. WHO includes phytotherapy in its health programmes and gives basic procedures for the validation of herbal drugs in developing countries. Eastern countries like India and China have well-established herbal industries and Latin American countries have been carrying out research programs in medicinal plants and their standardisation procedures. In Germany, 50% of phytomedicinal products are sold on medical prescription and the cost being refunded by health insurance companies. In North American countries, phytomedicinal products are sold as .health foods. Consumers and professionals have struggled to change this by gathering information about the efficacy and safety of these products and new guidelines for their registration are now part of FDA policy. In 1997, the North American market for products of plant origin reached US$ 2